JP2022508513A5 - - Google Patents
Info
- Publication number
- JP2022508513A5 JP2022508513A5 JP2021542070A JP2021542070A JP2022508513A5 JP 2022508513 A5 JP2022508513 A5 JP 2022508513A5 JP 2021542070 A JP2021542070 A JP 2021542070A JP 2021542070 A JP2021542070 A JP 2021542070A JP 2022508513 A5 JP2022508513 A5 JP 2022508513A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- compound
- administered
- pharmaceutically acceptable
- cocrystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862739809P | 2018-10-01 | 2018-10-01 | |
| US62/739,809 | 2018-10-01 | ||
| US201862773980P | 2018-11-30 | 2018-11-30 | |
| US62/773,980 | 2018-11-30 | ||
| PCT/US2019/053721 WO2020072334A1 (en) | 2018-10-01 | 2019-09-30 | Combination therapy for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022508513A JP2022508513A (ja) | 2022-01-19 |
| JP2022508513A5 true JP2022508513A5 (cg-RX-API-DMAC7.html) | 2022-10-13 |
| JP7466549B2 JP7466549B2 (ja) | 2024-04-12 |
Family
ID=69945395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021542070A Active JP7466549B2 (ja) | 2018-10-01 | 2019-09-30 | がん治療のための併用療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11529339B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3860610A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7466549B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN112839658B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019351811B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021006318A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3114401A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL281845B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021003842A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202103141YA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020072334A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3114401A1 (en) | 2018-10-01 | 2020-04-09 | Celgene Corporation | Combination therapy for the treatment of cancer |
| KR20220110243A (ko) * | 2019-12-02 | 2022-08-05 | 셀진 코포레이션 | 암의 치료를 위한 요법 |
| CN115916191B (zh) * | 2020-06-25 | 2026-06-23 | 新基公司 | 用组合疗法治疗癌症的方法 |
| US20260098035A1 (en) | 2022-09-20 | 2026-04-09 | Celgene Corporation | Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same |
| WO2025195464A1 (zh) * | 2024-03-21 | 2025-09-25 | 上海惠康济民生物医药技术有限公司 | 取代的异吲哚啉类化合物、制备方法、药物组合物及应用 |
| CN119161336B (zh) * | 2024-07-24 | 2025-09-05 | 四川大学 | 一种作为Blimp1抑制剂的小分子化合物及其用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2681633C (en) | 2007-03-20 | 2018-01-09 | Celgene Corporation | 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same |
| SG183257A1 (en) | 2010-02-11 | 2012-09-27 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| TWI509247B (zh) | 2010-03-12 | 2015-11-21 | 西建公司 | 利用雷那度胺(lenalidomide)治療非霍奇金氏淋巴瘤之方法及作為預測子之基因及蛋白質生物標記 |
| SI2683384T1 (sl) | 2011-03-11 | 2016-05-31 | Celgene Corporation | Metode zdravljenja raka z uporabo 3-(5-amino-2-metil-4-okso-4H-kinazolin-3-il)-piperidin-2,6-diona |
| HK1211577A1 (en) | 2012-08-09 | 2016-05-27 | 细胞基因公司 | Processes for the preparation of (s)-3-4- ((4-(morpholinomethyl) benzyl)oxy)-1-oxoisoindolin-2-yl) piperidine-2,6-dione and pharmaceutically acceptable forms thereof |
| US20150038511A1 (en) | 2012-08-09 | 2015-02-05 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
| LT2882737T (lt) | 2012-08-09 | 2019-04-25 | Celgene Corporation | (s)-3-(4-((4-morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il)piperidin-2,6-diono hidrochlorido kieta forma |
| KR20210073616A (ko) | 2012-08-09 | 2021-06-18 | 셀진 코포레이션 | 면역-관련 및 염증성 질환의 치료 |
| UA116544C2 (uk) | 2012-08-09 | 2018-04-10 | Селджин Корпорейшн | Спосіб лікування раку з використанням 3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
| US20140343058A1 (en) | 2012-08-09 | 2014-11-20 | Celgene Corporation | Treatment of systemic lupus erythematosus |
| UA118255C2 (uk) * | 2012-12-07 | 2018-12-26 | Санофі | Композиція, яка містить антитіло до cd38 і леналідомід |
| UA117141C2 (uk) | 2013-10-08 | 2018-06-25 | Селджин Корпорейшн | Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
| TWI745271B (zh) | 2014-05-19 | 2021-11-11 | 美商西建公司 | 全身紅斑性狼瘡之治療 |
| AU2015305449B2 (en) | 2014-08-22 | 2021-05-06 | Celgene Corporation | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies |
| US11124577B2 (en) * | 2016-11-02 | 2021-09-21 | Engmab Sàrl | Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma |
| CA3114401A1 (en) | 2018-10-01 | 2020-04-09 | Celgene Corporation | Combination therapy for the treatment of cancer |
| EA202190865A1 (ru) * | 2018-11-30 | 2021-07-01 | Селджин Корпорейшн | Комбинированная терапия для лечения рака |
-
2019
- 2019-09-30 CA CA3114401A patent/CA3114401A1/en active Pending
- 2019-09-30 EP EP19869422.6A patent/EP3860610A4/en active Pending
- 2019-09-30 BR BR112021006318A patent/BR112021006318A2/pt unknown
- 2019-09-30 JP JP2021542070A patent/JP7466549B2/ja active Active
- 2019-09-30 CN CN201980065270.1A patent/CN112839658B/zh active Active
- 2019-09-30 US US16/588,318 patent/US11529339B2/en active Active
- 2019-09-30 WO PCT/US2019/053721 patent/WO2020072334A1/en not_active Ceased
- 2019-09-30 MX MX2021003842A patent/MX2021003842A/es unknown
- 2019-09-30 AU AU2019351811A patent/AU2019351811B2/en active Active
- 2019-09-30 SG SG11202103141YA patent/SG11202103141YA/en unknown
- 2019-09-30 IL IL281845A patent/IL281845B2/en unknown
-
2022
- 2022-11-09 US US17/983,762 patent/US12605372B2/en active Active
-
2026
- 2026-03-20 US US19/574,120 patent/US20260216161A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10632112B2 (en) | Combination therapy for treatment of HBV infections | |
| US12077554B2 (en) | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer | |
| JP2022537551A5 (cg-RX-API-DMAC7.html) | ||
| TWI633887B (zh) | 用於預防及/或治療多囊性腎臟病之藥物 | |
| US10583129B2 (en) | Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer | |
| JP2018531605A5 (cg-RX-API-DMAC7.html) | ||
| JP2024546605A (ja) | がんを治療するための併用療法の使用 | |
| JP2020523317A5 (cg-RX-API-DMAC7.html) | ||
| RU2358730C2 (ru) | Производное эпотилона для лечения гепатомы и других раковых заболеваний | |
| JP2020515523A5 (cg-RX-API-DMAC7.html) | ||
| CN1181819C (zh) | 使用五氟苯磺酰胺的综合疗法 | |
| EP4349341A1 (en) | Pharmaceutical preparation for preventing or treating pulmonary fibrosis | |
| CN118946371A (zh) | 靶向psma的放射性药物和检查点抑制剂的组合疗法 | |
| JP2023011549A (ja) | クマリン誘導体を含有する、細胞増殖性疾患の治療又は予防用医薬 | |
| CN105616411A (zh) | 治疗结肠癌的组合物及其应用 | |
| US20220296557A1 (en) | Combinations of bcl-2/bcl-xl inhibitors and related uses | |
| CN1711090A (zh) | 用于治疗慢性淋巴细胞白血病的氮芥类似物和甲磺酸依马替尼的组合 | |
| JP2019038858A (ja) | ペマフィブラートを含有する医薬 | |
| JP2024505515A5 (cg-RX-API-DMAC7.html) | ||
| TW201618777A (zh) | 脂質異常症治療劑 | |
| CN102869353A (zh) | 自身免疫疾病的治疗 | |
| JP2016210688A (ja) | 放射性抗腫瘍剤、及び、抗腫瘍用キット | |
| WO2021217084A1 (en) | Use of nitro-fatty acids and analogues thereof for the prevention and/or treatment of acute lung injury and/or sars-cov-2 infection | |
| RU2008111064A (ru) | Кристаллические формы дельта и ипсилон иматинибмезилата | |
| HK1225968B (en) | Combination therapy for treatment of hbv infections |